MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
-24.96%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$373M
AUM Growth
+$373M
(-32%)
Cap. Flow
-$15.2M
Cap. Flow
% of AUM
-4.07%
Top 10 Holdings %
Top 10 Hldgs %
67.37%
Holding
38
New
5
Increased
4
Reduced
17
Closed
1
Top Buys
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$5.9M |
| 2 |
Arcutis Biotherapeutics
ARQT
|
$4.98M |
| 3 |
Relmada Therapeutics
RLMD
|
$3.73M |
| 4 |
Phathom Pharmaceuticals
PHAT
|
$2.63M |
| 5 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$2.54M |
Top Sells
| 1 |
MEI Pharma
MEIP
|
$33M |
| 2 |
iTeos Therapeutics
ITOS
|
$3.18M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
$372K |
| 4 |
Cytokinetics
CYTK
|
$295K |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
$288K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cullinan Oncology
CGEM
$445M
| $80.1M | 21.49% | 7,648,268 | – | – |
|
|
2
iTeos Therapeutics
ITOS
| $56.2M | 15.08% | 1,745,943 -98,784 | -5% | -$3.18M |
|
3
Merus
MRUS
$4.98B
| $24.3M | 6.52% | 919,482 -7,820 | -0.8% | -$207K |
|
4
Repare Therapeutics
RPTX
$71.7M
| $23.4M | 6.27% | 1,639,849 | – | – |
|
|
HARP
5
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $15.9M | 4.26% | 3,196,707 | – | – |
|
6
Intellia Therapeutics
NTLA
$1.22B
| $11.6M | 3.11% | 159,409 -1,118 | -0.7% | -$81.2K |
|
7
Werewolf Therapeutics
HOWL
$59.9M
| $10.5M | 2.82% | 2,388,011 | – | – |
|
|
8
BioCryst Pharmaceuticals
BCRX
$1.74B
| $10.4M | 2.79% | 639,089 -22,862 | -3% | -$372K |
|
|
TPTX
9
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $9.43M | 2.53% | 351,350 +80,000 | +29% | +$2.15M |
|
|
TCRR
10
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $9.3M | 2.5% | 3,370,982 | – | – |
|
11
Geron
GERN
$893M
| $8.36M | 2.24% | 6,149,277 +525,388 | +9% | +$715K |
|
|
12
Cytokinetics
CYTK
$4.23B
| $8.25M | 2.22% | 224,246 -8,022 | -3% | -$295K |
|
|
13
Crinetics Pharmaceuticals
CRNX
$2.92B
| $8.05M | 2.16% | 366,676 -13,116 | -3% | -$288K |
|
14
Travere Therapeutics
TVTX
$1.56B
| $7.16M | 1.92% | 277,950 -9,943 | -3% | -$256K |
|
15
Harmony Biosciences
HRMY
$2.12B
| $6.69M | 1.8% | 137,517 -4,920 | -3% | -$239K |
|
|
GTHX
16
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $6.51M | 1.75% | 856,798 | – | – |
|
17
Mirum Pharmaceuticals
MIRM
$3.71B
| $6.35M | 1.71% | 288,531 -10,321 | -3% | -$227K |
|
|
RETA
18
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $5.9M | 1.58% | +180,000 | New | +$5.9M |
|
19
Y-mAbs Therapeutics
YMAB
$388M
| $5.27M | 1.41% | 443,702 -2,755 | -0.6% | -$32.7K |
|
|
20
Arcutis Biotherapeutics
ARQT
$1.86B
| $4.98M | 1.34% | +258,500 | New | +$4.98M |
|
21
ADC Therapeutics
ADCT
$345M
| $4.91M | 1.32% | 334,384 -3,012 | -0.9% | -$44.2K |
|
22
Amicus Therapeutics
FOLD
$2.34B
| $4.69M | 1.26% | 495,603 -17,730 | -3% | -$168K |
|
23
Verastem
VSTM
$569M
| $4.58M | 1.23% | 3,244,650 -26,882 | -0.8% | -$37.9K |
|
|
ONCR
24
DELISTED
Oncorus, Inc.
ONCR
| $4.23M | 1.14% | 2,377,031 | – | – |
|
25
Axsome Therapeutics
AXSM
$6.05B
| $4.13M | 1.11% | 99,834 -3,571 | -3% | -$148K |
|